Scarica l'app Stockscreener
9.08
1.84%
-0.17
Dopo l'orario di chiusura:
9.13
0.05
+0.55%
Precedente Chiudi:
$9.25
Aprire:
$9.34
Volume 24 ore:
1.38M
Relative Volume:
0.66
Capitalizzazione di mercato:
$1.66B
Reddito:
$314.85M
Utile/perdita netta:
$12.01M
Rapporto P/E:
138.63
EPS:
0.0655
Flusso di cassa netto:
$47.52M
1 W Prestazione:
-0.22%
1M Prestazione:
+5.83%
6M Prestazione:
+50.33%
1 anno Prestazione:
+9.27%
Intervallo 1D:
$9.035
$9.34
Intervallo di 1 settimana:
$9.00
$11.33
Portata 52W:
$5.25
$11.33
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Nome
Xeris Biopharma Holdings Inc
Settore
Telefono
844-445-5704
Indirizzo
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
9.08 | 1.66B | 314.85M | 12.01M | 47.52M | 0.0655 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2023-08-28 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Craig Hallum | Buy |
| 2021-11-17 | Iniziato | SVB Leerink | Outperform |
| 2021-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-02-18 | Iniziato | Piper Sandler | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Leerink Partners | Outperform |
| 2018-07-16 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Xeris Biopharma Holdings Inc Borsa (XERS) Ultime notizie
Lundbeck is weighing a bid for Xeris Biopharma, per people familiar - Briefs Finance
Sources: Lundbeck interested in acquiring Xeris BiopharmaBN - marketscreener.com
Xeris Biopharma Holdings, Inc. (XERS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports - Investing.com
Xeris Biopharma Acquisition Rumors Spark Interest - Intellectia AI
Xeris Biopharma (XERS) Stock Jumps 6% Amid Acquisition Interest from Lundbeck - GuruFocus
Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’ - Yahoo Finance
Lundbeck expresses interest in buying Xeris, Bloomberg News reports - Yahoo Finance
Lundbeck Said to Explore Potential Xeris Biopharma Acquisition, Bloomberg Reports - marketscreener.com
Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition - Yahoo Finance
Lundbeck Is Said to Express Interest in Xeris Biopharma - Bloomberg.com
Xeris Biopharma stock hits 52-week high at 10.08 USD By Investing.com - Investing.com Nigeria
A Xeris Biopharma (XERS) officer proposes a share sale valued at $637,000. - Stock Titan
Xeris Biopharma Holdings stock rises 6.65 percent on Nasdaq - AD HOC NEWS
ETFs Investing in Xeris Biopharma Holdings, Inc. Stocks - TradingView
Xeris Biopharma stock rises 1.62 percent on September 24 - AD HOC NEWS
XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Chart - ChartMill
Xeris Biopharma (XERS) Edges Higher to $8.20 as Shares Test Upper RangeIPO Entry Watch - dars.gov.et
Xeris Biopharma stock gains on higher targets and August results - AD HOC NEWS
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: A 50% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Xeris Biopharma Holdings stock gains after strong Q2 revenue growth - AD HOC NEWS
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial StrategySlideshow (NASDAQ:XERS) 2026-09-11 - Seeking Alpha
XERS Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocus
Oppenheimer reiterates Xeris Pharmaceuticals stock rating on XP-8121 outlook - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - cnn.com
Xeris Biopharma Holdings, Inc. (XERS) stock price, news, quote and history - uk.finance.yahoo.com
Xeris Biopharma Holdings, Inc. at XP-8121 Program Overview Transcript - GuruFocus
XERS Looks 54.7% Overvalued on GF Value™ as Clinical Update Appr - GuruFocus
Millions of thyroid patients may get weekly shot option from Xeris (NASDAQ: XERS) - Stock Titan
An estimated 3 to 5 million lack thyroid control. Xeris is developing a weekly injection. - Stock Titan
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism - businesswire.com
Xeris Biopharma Holdings Inc. (XERS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Xeris Biopharma Holdings Inc (XERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares By Investing.com - Investing.com South Africa
Xeris Biopharma’s Beth Hecht sells $141,434 in company stock By Investing.com - Investing.com India
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares - Investing.com
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock By Investing.com - Investing.com Canada
Xeris Biopharma’s Beth Hecht sells $141,434 in company stock - Investing.com
Xeris Biopharma CFO Steven Pieper Executes Sale of 5,000 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma CLO Beth Hecht Sells 16,666 Shares via 10b5-1 Trading Plan - kalkinemedia.com
Xeris Biopharma COO Kevin McCulloch Sells 15,000 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma Holdings Inc. (XERS) Peer Comparison – Compare with Others - Value Research
Xeris Biopharma stock holds at $8.48 after earnings miss - ad-hoc-news.de
Xeris Biopharma Holdings Inc. (XERS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Xeris Biopharma Holdings, Inc. (0A8E.L) Stock Price, News, Quote & History - Yahoo Finance
Xeris Announces Details for XP-8121 Program Overview Webinar - Yahoo Finance
GENB Stock Price and Chart — NASDAQ:GENB - TradingView
Xeris (XERS) Earnings Report: Profit Per Share Falls Below Its Benchmark in the Available Record; Price Reaction - vinanet.vn
XERS | Xeris Biopharma Holdings, Inc. FinancialsRevenue Breakdown - Quiver Quantitative
Xeris Biopharma CEO John Patrick Shannon Jr. Reports Share Withholding for RSU Tax Settlement - Kalkine Media
XERS Maintains Overweight Rating by Barclays -- Price Target Rai - GuruFocus
Xeris Biopharma Holdings Inc Azioni (XERS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xeris Biopharma Holdings Inc Azioni (XERS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McCulloch Kevin | See Remarks |
Sep 28 '26 |
Sale |
10.00 |
25,000 |
250,000 |
1,614,208 |
1.15%
5.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):